{"id":"clindamycin-phosphate-vaginal-cream-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Vulvovaginal irritation or itching"},{"rate":null,"effect":"Vaginal discharge or odor changes"},{"rate":"5-10","effect":"Vulvovaginal candidiasis (secondary yeast infection)"},{"rate":null,"effect":"Abdominal pain or cramping"}]},"_chembl":{"chemblId":"CHEMBL3184512","moleculeType":"Small molecule","molecularWeight":"504.97"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"When applied as a vaginal cream, clindamycin phosphate is converted to its active form and penetrates vaginal tissues to suppress the growth of anaerobic bacteria that cause bacterial vaginosis. By disrupting bacterial protein synthesis, it restores the normal vaginal flora balance. The 2% formulation delivers therapeutic concentrations directly to the vaginal epithelium with minimal systemic absorption.","oneSentence":"Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby killing or inhibiting the growth of anaerobic bacteria and some gram-positive organisms responsible for bacterial vaginosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:05.556Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial vaginosis in non-pregnant women"},{"name":"Bacterial vaginosis in pregnant women (second and third trimester)"}]},"trialDetails":[{"nctId":"NCT07247851","phase":"NA","title":"Title of the Protocol: Combined Use of Vaginal Clindamycin Cream and Oral Metronidazole Versus Oral Metronidazole","status":"COMPLETED","sponsor":"Ain Shams Maternity Hospital","startDate":"2024-01-10","conditions":"Bacterial Vaginosis","enrollment":100},{"nctId":"NCT05963711","phase":"NA","title":"The Genital Microbiome of Male Partners of Women with Recurrent BV Undergoing Vaginal Microbiome Transplantation","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2022-10-17","conditions":"Bacterial Vaginosis, Microbial Colonization","enrollment":100},{"nctId":"NCT02210689","phase":"PHASE3","title":"A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2014-01","conditions":"BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency","enrollment":604},{"nctId":"NCT01245322","phase":"PHASE4","title":"Treatment of Bacterial Vaginosis Combined With Human Lactobacilli","status":"COMPLETED","sponsor":"Skaraborg Hospital","startDate":"2007-01","conditions":"Bacterial Vaginosis","enrollment":75},{"nctId":"NCT01125410","phase":"PHASE3","title":"Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis","status":"COMPLETED","sponsor":"Medinova AG","startDate":"2007-01","conditions":"Bacterial Vaginosis","enrollment":321}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"clindamycin phosphate vaginal cream 2%","genericName":"clindamycin phosphate vaginal cream 2%","companyName":"Actavis Inc.","companyId":"actavis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby killing or inhibiting the growth of anaerobic bacteria and some gram-positive organisms responsible for bacterial vaginosis. Used for Bacterial vaginosis in non-pregnant women, Bacterial vaginosis in pregnant women (second and third trimester).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}